In industrialised countries like in Europe, acute lymphoblastic leukaemia is the most common form of cancer in children.

An international research consortium lead by paediatric oncologists from the Universities of Zurich and Hannover has now succeeded in decoding a specific form of this leukaemia, which is regarded as incurable, and in obtaining insights for new therapeutic possibilities.

Acute lymphoblastic leukaemia (ALL) frequently develops between the age of two and three.

This leukaemia has various forms, which differ through certain changes in the genetic material of the leukaemia cells.

A team of scientists involved in a joint international project headed by Jean-Pierre Bourquin, a paediatric oncologist from the University Children’s Hospital Zurich, and Martin Stanulla, a professor at Hannover Medical School, has now succeeded in decoding the genome and transcriptome of an as yet incurable sub-type of acute lymphoblastic leukaemia.

These results were achieved in collaboration with leading experts in the field, Marie Laure Yaspo, a research group leader at the Max Plank Institute for Molecular Genetics in Berlin, Arndt Borkhardt, a professor at the University of Düsseldorf, Jan Korbel a professor at the European Molecular Biology Laboratory in Heidelberg and André Franke from the University of Kiel.

The two genes TCF3 and HLF are already known to be fused together aberrantly in this subtype of acute lymphoblastic leukaemia.

This change in the genetic code makes the leukaemia resistant to all current treatments.

The scientists have now discovered that other DNA areas are also changed in addition to the two aberrantly fused genes and that the activity of key genes was modified thus determining a novel program associated to the leukaemia cells. 

A wolf in sheep’s clothing

Modifications of genes that control the development and promote the growth of highly specific blood defence cells, so-called B-lymphocytes, were evident in the leukaemia cells studied.

The interplay between the pathogenic fusion of TCF3 with HLF and newly identified alterations triggers a previously undetected reprogramming of the leukaemia cells to a very early, stem-cell-like developmental stage, which is not externally visible on the cells.

“This form of leukaemia might be described as a kind of ‘wolf in sheep’s clothing’,” stresses Martin Stanulla.

“These key findings could be made, in particular, by reading out the messenger molecules synthesised in the tumour cells, a powerful technique allowing not only a deeper understanding of the genetic program specifying the behaviour of tumour cells, but also of therapeutic entry points” adds Marie-Laure Yaspo.

The group of Jean-Pierre Bourquin developed a humanised mouse model at the University Children’s Hospital in Zurich that enables researchers to explore leukaemias in conditions that are very similar to the situations encountered in humans.

“In other words, we created a model to accelerate the discovery of more personalised treatment options,” explains Jean-Pierre Bourquin.

The human leukaemia cells growing in the mouse retain the crucial genetic changes and, according to Bourquin, therefore constitute a realistic possibility to examine new courses of therapy in a patient-oriented manner. 

Promising drug tests

On this basis, the Zurich researchers tested hundreds of novel drugs.

Some of them, which are still undergoing further clinical development, displayed a very positive effect.

One such drug is Venetoclax, which specifically targets the protein BCL2 relevant for the programmed cell death and already worked for other cancer strains.

In the mouse model, Venetoclax induced remissions of the disease, followed by prolonged phases without any signs of the disease if administered together with conventional chemotherapy for leukaemia.

“Further studies are now needed to test how the results of our study might be used for therapeutic possibilities,” says Bourquin.

“Our work just goes to show the great potential of coordinated, interdisciplinary research approaches involving cutting-edge technological possibilities for cancer research,” concludes Stanulla. 

The development of new courses of therapy in the humanised leukaemia model was supported by the Swiss National Science Foundation and the University of Zurich’s clinical research focus program “Human Hemato-Lymphatic Diseases”.

The genetic studies were funded by the German Federal Office for Radiation Protection via the environmental research program of the German Federal Environment Ministry and by the Max Planck Institute for Molecular Genetics.

Source: University of Zurich